3
Statement for the JBDS-IP guidelines
JBDS guidelines have been developed to advise on the care process for people with diabetes
currently under hospital care.
The guideline recommendations have been developed and reviewed by a multidisciplinary
team led by the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) group. People
with diabetes have been involved in the development of the guidelines via stakeholder
events organised by Diabetes UK.
It is intended that the guideline will be useful to clinicians and service commissioners in
planning, organising and delivering high quality diabetes care. There remains, however, an
individual responsibility of healthcare professionals to make decisions appropriate to the
circumstance of the individual, informed by them and/or their guardian or carer and taking
full account of their medical condition and treatment.
When implementing this guideline full account should be taken of the local context and
in line with statutory obligations required of the organisation and individual. No part of
the guideline should be interpreted in a way that would knowingly put staff, those with
diabetes or anyone else at risk.
Copyright statement
These guidelines are free for anyone to distribute, amend and use. However, we would
encourage those who use them to acknowledge the source of the document and cite the
Joint British Diabetes Societies for Inpatient Care.
The Guidelines produced by the Joint British Diabetes Societies for Inpatient Care are
licensed under CC BY-NC 4.0
Cite as:
Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group. Using technology to
support diabetes care in hospital: A guideline from the Joint British Diabetes Societies
for Inpatient Care (JBDS-IP) group and Diabetes Technology Network (DTN). Joint British
Diabetes Societies for Inpatient Care (JBDS-IP) Group: 2024.
Version
1.0 March 2024 First publication (this document)
All enquiries regarding this document should be addressed to the Joint British Diabetes
Societies for Inpatient Care (JBDS-IP) group
[email protected]
Conflict of interest statement
AL has received payments for speaking and advisory boards from Insulet, Dexcom, Abbott
Diabetes Care, Novo Nordisk, Sanofi and Institutional Research Support from Abbott
Diabetes Care, Novo Nordisk. DF is the national lead for the UK diabetes care accreditation
programme and has received speaker honoraria from AstraZeneca, Novo Nordisk, and
Sanofi Diabetes. SM is appointed to the Board of Trustees at the Diabetes Research &
Wellness Foundation and is in receipt of funds from Dexcom for an investigator-initiated
research study. GR has received personal fees from Abbott Diabetes Care, Sanofi Aventis
and Eli Lilly. PC has received personal fees from Abbott Diabetes Care, Dexcom, Diasend, Eli
Lilly, Insulet, Medtronic, Novo Nordisk, Roche and Sanofi Aventis. KD has received speaker
fees, travel or taken part in advisory boards for AstraZeneca, Sanofi Diabetes, Boehringer
Ingelheim, Lilly, and Novo Nordisk. PA has no conflicts of interest.